

Press release from the Extraordinary General Meeting in Vimian Group AB (publ) on 11 June 2025

Vimian held an Extraordinary General Meeting today 11 June 2025. The Extraordinary General Meeting was held by physical presence of shareholders and with the option for shareholders to exercise their voting rights by advance voting (postal voting). The General Meeting in Vimian Group AB (publ) resolved the following:

Adoption of new Articles of Association

The General Meeting resolved, in accordance with the Board of Director's proposal, to adopt new Articles of Association. In brief, the amendment introduces new reclassifiable and redeemable share classes for use in Vimian's incentive program.

Adoption of long-term performance-based share program

The General Meeting resolved, in accordance with the Board of Director's proposal, to adopt a new long-term performance-based share program, LTIP 2025/2028, for employees and consultants in the Vimian group. As part of the adoption of the incentive program, it was also resolved to carry out directed share issues and repurchases of own shares, as well as transfers of own shares to participants in LTIP 2025/2028.

Adoption of new remuneration guidelines

The General Meeting resolved, in accordance with the proposal by the Board of Directors, to adopt new remuneration guidelines. The remuneration guidelines are in all material aspects consistent with the previously applicable guidelines but have been adjusted to clarify that incentive programs may be adopted not only by the Annual General Meeting, but also by an Extraordinary General Meeting, and to clarify that the notice period for certain senior executives may differ from the general notice period of three to six months, due to local laws and practices.

For further information, please contact:

Maria Dahllöf Tullberg

Head of IR, Communications & Sustainability

maria.tullberg@vimian.com

+46 73 626 88 86

About Vimian

Vimian is a global animal health company covering four essential and rapidly evolving areas: Specialty Pharma, MedTech, Veterinary Services and Diagnostics. At Vimian, we believe that every animal deserves the best available care. We bring pioneering and entrepreneurial businesses together to make the market's most innovative offerings accessible to more animal health professionals and pet owners. Headquartered in Stockholm, Sweden, Vimian reaches over 17,000 veterinary clinics and laboratories, sells to over 80 markets, has 1,200 employees and annual revenues of approximately EUR 375 million. For more information, please visit: www.vimian.com.

Attachments

[Press release from the Extraordinary General Meeting in Vimian Group AB \(publ\) on 11 June 2025](#)